Selectivity problems with drugs acting on cardiac Na+ and Ca2+ channels

Current Medicinal Chemistry

Volumn 20, Issue 20, 2013, Pages 2552-2571

  Hegyi, Bence ^a   Komáromi, István ^b   Nánási, Peter P ^a   Szentandrássy, Norbert ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Ca2+ channels; Cardioactive drugs; Channel structures; Ion selectivity; Na+ channels; Tetrodotoxin

Indexed keywords

ARTICAINE; BATRACHOTOXIN; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CEVADINE; DIGOXIN; FLECAINIDE; GALLOPAMIL; GUANIDINE; INOTROPIC AGENT; ISOPRENALINE; LIDOCAINE; MEXILETINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; OUABAIN; PHENYTOIN; PROPAFENONE; QUINIDINE; RANOLAZINE; ROPIVACAINE; SAXITOXIN; SODIUM CHANNEL BLOCKING AGENT; TETRACAINE; TETRODOTOXIN; UNINDEXED DRUG; VERAPAMIL; VERATRIDINE;

ACTION POTENTIAL; ACUTE HEART INFARCTION; AMINO ACID SEQUENCE; ARTICLE; CARDIOTOXICITY; CHEMICAL STRUCTURE; CROSS REACTION; DORSAL ROOT; DRUG BINDING; DRUG PENETRATION; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTRIC POTENTIAL; ENANTIOMER; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART VENTRICLE TACHYCARDIA; HIPPOCAMPAL CA1 REGION; HUMAN; HYDROPHILICITY; INOTROPISM; MEMBRANE POTENTIAL; NONHUMAN; PURKINJE FIBER; STABLE ANGINA PECTORIS; STEADY STATE; SURFACE CHARGE; TACHYCARDIA; VOLTAGE CLAMP; XENOPUS;

ANESTHETICS, LOCAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BATRACHOTOXINS; CALCIUM CHANNELS, L-TYPE; HUMANS; MYOCARDIUM; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PROTEIN BINDING; SAXITOXIN; TETRODOTOXIN; VERATRIDINE;

EID: 84877966577     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990123     Document Type: Article

References (189)

1. Catterall W.A.; Goldin A.L.; Waxman S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005 57(4) 397-409. (Pubitemid 43036431)
2. Zimmer T. Effects of tetrodotoxin on the mammalian cardiovascular system. Mar. Drugs 2010 8(3) 741-762.
3. Andavan G.S.; Lemmens-Gruber R. Voltage-gated sodium channels: mutations channelopathies and targets. Curr. Med. Chem. 2011 18(3) 377-397.
4. Trimmer J.S.; Cooperman S.S.; Tomiko S.A.; Zhou J.Y.; Crean S.M.; Boyle M.B.; Kallen R.G.; Sheng Z.H.; Barchi R.L.; Sigworth F.J.; Goodman R.H.; Agnew W.S.; Mendel G. Primary structure and functional expression of a mammalian skeletal muscle sodium channel. Neuron 1989 3(1) 33-49.
5. Chahine M.; Bennett P.B.; George A.L.; Horn R. Functional expression and properties of the human skeletal muscle sodium channel. Pflugers Arch. 1994 427(1-2) 136-142. (Pubitemid 24131564)
6. Satin J.; Kyle J.W.; Chen M.; Bell P.; Cribbs L.L.; Fozzard H.A.; Rogart R.B. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science 1992 256(5060) 1202-1205.
7. Baer M.; Best P.M.; Reuter H. Voltage-dependent action of tetrodotoxin in mammalian cardiac muscle. Nature 1976 263(5575) 344-345.
8. Brown A.M.; Lee K.S.; Powell T. Sodium current in single rat heart muscle cells. J. Physiol. 1981 318 479-500. (Pubitemid 11059747)
9. Haufe V.; Chamberland C.; Dumaine R. The promiscuous nature of the cardiac sodium current. J. Mol. Cell. Cardiol. 2007 42(3) 469-477. (Pubitemid 46349127)
10. Penzotti J.L.; Lipkind G.; Fozzard H.A.; Dudley S.C. Specific neosaxitoxin interactions with the Na+ channel outer vestibule determined by mutant cycle analysis. Biophys. J. 2001 80(2) 698-706. (Pubitemid 32128323)
11. Hille B. Ion channels of excitable membranes. 3rd ed.; Sinauer Associates Inc.; Sunderland 2001.
12. Haverinen J.; Hassinen M.; Vornanen M. Fish cardiac sodium channels are tetrodotoxin sensitive. Acta Physiol. (Oxf) 2007 191(3) 197-204. (Pubitemid 47568905)
13. Su Z.; Sheets M.; Ishida H.; Li F.; Barry W.H. Saxitoxin blocks L-type ICa. J. Pharmacol. Exp. Ther. 2004 308(1) 324-329.
14. Aggarwal R.; Shorofsky S.R.; Goldman L.; Balke C.W. Tetrodotoxin- blockable calcium currents in rat ventricular myocytes; a third type of cardiac cell sodium current. J. Physiol. 1997 505(Pt 2) 353-369. (Pubitemid 28043383)
15. Alvarez J.L.; Salinas-Stefanon E.; Orta G.; Ferrer T.; Talavera K.; Galán L.; Vassort G. Occurrence of a tetrodotoxin-sensitive calcium current in rat ventricular myocytes after long-term myocardial infarction. Cardiovasc. Res. 2004 63(4) 653-661. (Pubitemid 39078679)
16. Chen-Izu Y.; Sha Q.; Shorofsky S.R.; Robinson S.W.; Wier W.G.; Goldman L.; Balke C.W. ICa(TTX) channels are distinct from those generating the classical cardiac Na+ current. Biophys. J. 2001 81(5) 2647-2659. (Pubitemid 33020052)
17. Goldman L.; Aggarwal R.; Shorofsky S.R.; Balke C.W. A new cardiac sodium current component in rat ventricular cells. Biophys. J. 1997 72 A110.
18. Guatimosim S.; Sobie E.A.; dos Santos Cruz J.; Martin L.A.; Lederer W.J. Molecular identification of a TTX-sensitive Ca2+ current. Am. J. Physiol. Cell. Physiol. 2001 280(5) C1327-1339.
19. Heubach J.F.; Köhler A.; Wettwer E.; Ravens U. T-Type and tetrodotoxin-sensitive Ca2+ currents coexist in guinea pig ventricular myocytes and are both blocked by mibefradil. Circ. Res. 2000 86(6) 628-635. (Pubitemid 30208429)
20. Santana L.F.; Gómez A.M.; Lederer W.J. Ca2+ flux through promiscuous cardiac Na+ channels: slip-mode conductance. Science 1998 279(5353) 1027-1033. (Pubitemid 28113304)
21. Sha Q.; Robinson S.W.; McCulle S.L.; Shorofsky S.R.; Welling P.A.; Goldman L.; Balke C.W. An antisense oligonucleotide against H1 inhibits the classical sodium current but not ICa(TTX) in rat ventricular cells. J. Physiol. 2003 547(Pt 2) 435-440. (Pubitemid 36304977)
22. Chorvatova A.; Snowdon R.; Hart G.; Hussain M. Effects of pressure overload-induced hypertrophy on TTX-sensitive inward currents in guinea pig left ventricle. Mol. Cell. Biochem. 2004 261(1-2) 217-226. (Pubitemid 39004534)
23. Cole W.C.; Chartier D.; Martin M.; Leblanc N. Ca2+ permeation through Na+ channels in guinea pig ventricular myocytes. Am. J. Physiol. 1997 273(1 Pt 2) H128-137.
24. Leblanc N.; Chartier D.; Martin M.; Cole W.C. Ca2+ permeation through Na+ channels in guinea-pig ventricular myocytes. Biophys. J. 1996 70 A279.
25. Sun H.; Varela D.; Chartier D.; Ruben P.C.; Nattel S.; Zamponi G.W.; Leblanc N. Differential interactions of Na+ channel toxins with T-type Ca2+ channels. J. Gen. Physiol. 2008 132(1) 101-113.
26. Gaughan J.P.; Furukawa S.; Houser S.R. Tetrodotoxin-sensitive calcium current induces contraction in failed human ventricular myocytes. Circulation 1999 100 I-422.
27. Lemaire S.; Piot C.; Seguin J.; Nargeot J.; Richard S. Tetrodotoxin-sensitive Ca2+ and Ba2+ currents in human atrial cells. Receptors Channels 1995 3(2) 71-81.
28. Balke C.W.; Shorofsky S.R. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc. Res. 1998 37(2) 290-299. (Pubitemid 28165991)
29. Nargeot J. A tale of two (Calcium) channels. Circ. Res. 2000 86(6) 613-615. (Pubitemid 30208426)
30. Meves H.; Vogel W. Calcium inward currents in internally perfused giant axons. J. Physiol. 1973 235(1) 225-265.
31. Watanabe A; Tasaki I.; Singer I. Lerman L. Effects of tetrodotoxin on excitability of squid giant axons in sodium-free media. Science 1967 155(3758) 95-97.
32. Baker P.F.; Hodgkin A.L.; Ridgway E.B. Depolarization and calcium entry in squid giant axons. J. Physiol. 1971 218(3) 709-755.
33. Akaike N.; Takahashi K. Tetrodotoxin-sensitive calciumconducting channels in the rat hippocampal CA1 region. J. Physiol. 1992 450 529-546.
34. Farkas V.; Szentandrássy N.; Bárándi L.; Hegyi B.; Ruzsnavszky F.; Ruzsnavszky O.; Horváth B.; Bányász T.; Magyar J.; Márton I.; Nánási P.P. Interaction between Ca2+ channel blockers and isoproterenol on L-type Ca2+ current in canine ventricular cardiomyocytes. Acta Physiol. (Oxf.) 2012 206 42-50.
35. McNulty M.M.; Hanck D.A. State-dependent mibefradil block of Na+ channels. Mol. Pharmacol. 2004 66(6) 1652-1661.
36. Perez-Reyes E. Molecular physiology of low-voltage-Activated ttype calcium channels. Physiol. Rev. 2003 83(1) 117-161. (Pubitemid 36459879)
37. Vassort G.; Talavera K; Alvarez J.L. Role of T-type Ca2+ channels in the heart. Cell Calcium 2006 40(2) 205-220. (Pubitemid 43942302)
38. Hegyi B.; Bárándi L.; Komáromi I.; Papp F.; Horváth B.; Magyar J.; Bányász T.; Krasznai Z.; Szentandrássy N.; Nánási P.P. Tetrodotoxin blocks L-type Ca2+ channels in canine ventricular cardiomyocytes. Pflugers Arch. 2012 464 167-174.
39. Hofer A.M. Interactions between calcium and cAMP signaling. Curr. Med. Chem. 2012 19(34) 5768-5773.
40. Nattel S.; Maguy A.; Le Bouter S.; Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure myocardial infarction and atrial fibrillation. Physiol. Rev. 2007 87(2) 425-456. (Pubitemid 47084677)
41. Valdivia C.R.; Chu W.W.; Pu J.; Foell J.D.; Haworth R.A.; Wolff M.R.; Kamp T.J.; Makielski J.C. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J. Mol. Cell. Cardiol. 2005 38(3) 475-483. (Pubitemid 40331938)
42. Yoo S.H. Chromogranins and inositol 1,4,5-trisphosphatedependent Ca(2+)-signaling in cardiomyopathy and heart failure. Curr. Med. Chem. 2012 19(24) 4068-4073.
43. Zong X.G.; Dugas M.; Honerjäger P. Relation between veratridine reaction dynamics and macroscopic Na current in single cardiac cells. J. Gen. Physiol. 1992 99(5) 683-697.
44. Horackova M.; Vassort G. Transmembrane sodium movement and regulation of contraction in frog atrial muscle during the inotropic effect of veratrine. Recent. Adv. Stud. Cardiac. Struct. Metab. 1975 5 51-57.
45. Tsai H.Y.; Lin Y.T.; Chen Y.F.; Chen C.F. The interactions of paeoniflorin and veratrine on isolated rat atria. J. Ethnopharmacol. 1997 57(3) 169-176.
46. Marban E.; Tsien R.W. Enhancement of calcium current during digitalis inotropy in mammalian heart: positive feed-back regulation by intracellular calcium? J. Physiol. 1982 329 589-614. (Pubitemid 12057934)
47. Honerjäger P.; Reiter M. The relation between the effects of veratridine on action potential and contraction in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 1975 289(1) 1-28.
48. Yang. L.; Vassalle M. Effects of strophanthidin on the slow inward current in guinea-pig isolated ventricular myocytes. Clin. Exp. Pharmacol. Physiol. 1990 17(2) 105-120. (Pubitemid 20095550)
49. Nánási P.P.; Varró A.; Bryant S.H.; Lathrop D.A. Effects of veratrine on ion currents in single rabbit cardiomyocytes. Gen. Pharmacol. 1994 25 1667-1672.
50. Wasserstrom J.A.; Liberty K.; Kelly J.; Santucci P.; Myers M. Modification of cardiac Na+ channels by batrachotoxin: effects on gating kinetics and local anesthetic binding. Biophys. J. 1993 65(1) 386-395. (Pubitemid 23206071)
51. Nánási P.P.; Varró A.; Lathrop D.A.; Bryant S.H. Effects of veratridine on Na and Ca currents in frog skeletal muscle. Gen. Pharmacol. 1994 25 1661-1666.
52. Romey G.; Lazdunski M. Lipid-soluble toxins thought to be specific for Na+ channels block Ca2+ channels in neuronal cells. Nature 1982 297 79-80. (Pubitemid 12098148)
53. Long W.B.; Rosenblum S.; Grady I.P. Successful resuscitation of bupivacaine-induced cardiac arrest using cardiopulmonary bypass. Anesth. Analg. 1989 69(3) 403-406. (Pubitemid 20033470)
54. Yan A.C.; Newman R.D. Bupivacaine-induced seizures and ventricular fibrillation in a 13-year-old girl undergoing wound debridement. Pediatr. Emerg. Care 1998 14(5) 354-355. (Pubitemid 28498715)
55. Levsky M.E.; Miller M.A. Cardiovascular collapse from low dose bupivacaine. Can. J. Clin. Pharmacol. 2005 12(3) e240-245.
56. Dudley M.H.; Fleming S.W.; Garg U.; Edwards J.M. Fatality involving complications of bupivacaine toxicity and hypersensitivity reaction. J. Forensic. Sci. 2011 56(5) 1376-1379.
57. Moller R.; Covino B.G. Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine a new amide local anesthetic. Anesthesiology 1990 72(2) 322-329. (Pubitemid 20058001)
58. Krikava I.; Jarkovsk J.; Stourac P.; Nováková M.; Sevcík P. The effects of lidocaine on bupivacaine-induced cardiotoxicity in the isolated rat heart. Physiol. Res. 2010 59 S65-69.
59. Moller R.A.; Covino B.G. Cardiac electrophysiologic effects of articaine compared with bupivacaine and lidocaine. Anesth. Analg. 1993 76(6) 1266-1273. (Pubitemid 23164077)
60. Mio Y.; Fukuda N.; Kusakari Y.; Amaki Y.; Tanifuji Y.; Kurihara S. Comparative effects of bupivacaine and ropivacaine on intracellular calcium transients and tension in ferret ventricular muscle. Anesthesiology 2004 101(4) 888-894. (Pubitemid 39288038)
61. Shibuya N.; Momose Y.; Ito Y. Effects of bupivacaine on contraction and membrane potential in isolated canine papillary muscles. Pharmacology 1993 47(3) 158-166. (Pubitemid 23217290)
62. Shibuya N.; Hatakeyama N.; Yamazaki M.; Masuda A.; Satone T.; Ito Y.; Momose Y. Effects of bupivacaine on Na+ and Ca2+ currents in single canine ventricular cells. Masui 1995 44(2) 193-199.
63. Szabó A.; Szentandrássy N.; Birinyi P.; Horváth B.; Szabó G.; Bányász T.; Márton I.; Magyar J.; Nánási P.P. Effects of ropivacaine on action potential configuration and ion currents in isolated canine ventricular cardiomyocytes. Anesthesiology 2008 108(4) 693-702. (Pubitemid 351440591)
64. Dyhre H.; Lng M.; Wallin R.; Renck H. The duration of action of bupivacaine levobupivacaine ropivacaine and pethidine in peripheral nerve block in the rat. Acta Anaesthesiol. Scand. 1997 41(10) 1346-1352. (Pubitemid 27517670)
65. Mazoit J.X.; Boïco O.; Samii K. Myocardial uptake of bupivacaine: II. Pharmacokinetics and pharmacodynamics of bupivacaine enantiomers in the isolated perfused rabbit heart. Anesth. Analg. 1993 77(3) 477-482. (Pubitemid 23263517)
66. Zapata-Sudo G.; Trachez M.M.; Sudo R.T.; Nelson T.E. Is comparative cardiotoxicity of S(-) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca2+ channels? Anesth. Analg. 2001 92(2) 496-501. (Pubitemid 32127643)
67. Valenzuela C.; Snyders D.J.; Bennett P.B.; Tamargo J.; Hondeghem L.M. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Circulation 1995 92(10) 3014-3024.
68. Markham A.; Faulds D. Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs 1996 52(3) 429-449. (Pubitemid 26293866)
69. Bilir A.; Yelken B.; Kaygisiz Z.; Senturk Y. The effects of dopexamine in bupivacaine and ropivacaine induced cardiotoxicity in isolated rat heart. Saudi Med. J. 2006 27(8) 1194-1198. (Pubitemid 47045012)
70. David J.S.; Ferreti C.; Amour J.; Vivien B.; Eve O.; Petit P.; Riou B.; Gueugniaud P.Y. Effects of bupivacaine levobupivacaine and ropivacaine on myocardial relaxation. Can. J. Anaesth. 2007 54(3) 208-217. (Pubitemid 46784262)
71. Pitkanen M.; Feldman H.S.; Arthur G.R.; Covino B.G. Chronotropic and inotropic effects of ropivacaine bupivacaine and lidocaine in the spontaneously beating and electrically paced isolated perfused rabbit heart. Reg. Anesth. 1992 17(4) 183-192.
72. Royse C.F.; Royse A.G. The myocardial and vascular effects of bupivacaine levobupivacaine and ropivacaine using pressure volume loops. Anesth. Analg. 2005 101(3) 679-687. (Pubitemid 41208495)
73. Stehr S.N.; Christ T.; Rasche B.; Rasche S.; Wettwer E.; Deussen A.; Ravens U.; Koch T.; Hübler M. The effects of levosimendan on myocardial function in ropivacaine toxicity in isolated guinea pig heart preparations. Anesth. Analg. 2007 105(3) 641-647. (Pubitemid 47300837)
74. Graf B.M.; Abraham I.; Eberbach N.; Kunst G.; Stowe D.F.; Martin E. Differences in cardiotoxicity of bupivacaine and ropiva caine are the result of physicochemical and stereoselective properties. Anesthesiology 2002 96(6) 1427-1434. (Pubitemid 34587212)
75. Lefrant J.Y.; de La Coussaye J.E.; Ripart J.; Muller L.; Lalourcey L.; Peray P.A.; Mazoit X.; Sassine A.; Eledjam J.J. The comparative electrophysiologic and hemodynamic effects of a large dose of ropivacaine and bupivacaine in anesthetized and ventilated piglets. Anesth. Analg. 2001 93(6) 1598-1605. (Pubitemid 33111696)
76. Groban L.; Deal D.D.; Vernon J.C.; James R.L.; Butterworth J. Does local anesthetic stereoselectivity or structure predict myocardial depression in anesthetized canines? Reg. Anesth. Pain. Med. 2002 27(5) 460-468.
77. Porter J.M.; Markos F.; Snow H.M.; Shorten G.D. The efficacy of nicorandil calcium chloride and nitroglycerin in treatment of ropivacaine-induced cardiotoxicity. Eur. J. Anaesthesiol. 2003 20(12) 939-944. (Pubitemid 37500220)
78. Ding H.L.; Zeng Y.M.; Li X.D.; Jiang W.P.; Duan S.M. Effects of ropivacaine on sodium calcium and potassium currents in guinea pig ventricular myocytes. Acta Pharmacol. Sin. 2002 23(1) 50-54.
79. Hatakeyama N.; Yamada M.; Shibuya N.; Yamazaki M.; Yamamura S.; Sugaya M.; Momose Y. Effects of ropivacaine on membrane potential and voltage-dependent calcium channel current in single guinea-pig ventricular myocytes. J. Anesth. 2002 16(4) 273-278. (Pubitemid 36097853)
80. Szentandrássy N.; Szabó A.; Almássy J.; Jóna I.; Horváth B.; Szabó G.; Bányász T.; Márton I.; Nánási P.P.; Magyar J. Effects of articaine and ropivacaine on calcium handling and contractility in canine ventricular myocardium. Eur. J. Anaesthesiol. 2010 27(2) 153-161.
81. Szabó A.; Szentandrássy N.; Birinyi P.; Horváth B.; Szabó G.; Bányász T.; Márton I.; Nánási P.P.; Magyar J. Effects of articaine on action potential characteristics and the underlying ion currents in canine ventricular myocytes. Br. J. Anaesth. 2007 99(5) 726-733. (Pubitemid 351773222)
82. Carmeliet E.; Morad M.; Van der Heyden G.; Vereecke J. Electrophysiological effects of tetracaine in single guinea-pig ventricular myocytes. J. Physiol. 1986 376 143-161. (Pubitemid 16058127)
83. Eisner D.A.; Lederer W.J.; Noble D. Caffeine and tetracaine abolish the slow inward calcium current in sheep cardiac Purkinje fibres. J. Physiol. 1979 293 76P-77P. (Pubitemid 10225528)
84. Chapman R.A.; Leoty C. The effects of tetracaine on the membrane currents and contraction of frog atrial muscle. J. Physiol. 1981 317 475-486. (Pubitemid 12205887)
85. Venetucci L.A.; Trafford A.W.; Díaz M.E.; O'Neill S.C.; Eisner D.A. Reducing ryanodine receptor open probability as a means to abolish spontaneous Ca2+ release and increase Ca2+ transient amplitude in adult ventricular myocytes. Circ. Res. 2006 98(10) 1299-1305. (Pubitemid 43948085)
86. Vaughan Williams E.M. Subgroups of class 1 antiarrhythmic drugs. Eur. Heart. J. 1984 5(2) 96-98. (Pubitemid 14161448)
87. Furukawa T.; Koumi S.; Sakakibara Y.; Singer D.H.; Jia H.; Arentzen C.E.; Backer C.L.; Wasserstrom J.A. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. J. Mol. Cell. Cardiol. 1995 27(2) 831-846.
88. Arlock P. Actions of three local anaesthetics: lidocaine bupivacaine and ropivacaine on guinea pig papillary muscle sodium channels Vmax. Pharmacol. Toxicol. 1988 63(2) 96-104.
89. Sheldon R.S.; Cannon N.J.; Duff H.J. A receptor for type I antiarrhythmic drugs associated with rat cardiac sodium channels. Circ. Res. 1987 61(4) 492-497. (Pubitemid 17136185)
90. Ono K.; Kiyosue T.; Arita M. Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells. Life Sci. 1986 39(16) 1465-1470. (Pubitemid 16031642)
91. Chang G.J.; Su M.J.; Hung L.M.; Lee S.S. Cardiac electrophysiologic and antiarrhythmic actions of a pavine alkaloid derivative O-methyl-neocaryachine in rat heart. Br. J. Pharmacol. 2002 136(3) 459-471.
92. Chang G.J.; Wu M.H.; Wu Y.C.; Su M.J. Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine a natural aporphine alkaloid from Fissistigma glaucescens. Br. J. Pharmacol. 1996 118(7) 1571-1583.
93. Pugsley M.K.; Walker M.J.; Saint D.A. Block of Na+ and K+ currents in rat ventricular myocytes by quinacainol and quinidine. Clin. Exp. Pharmacol. Physiol. 2005 32(1-2) 60-65. (Pubitemid 40314471)
94. Scamps F.; Undrovinas A.; Vassort G. Inhibition of ICa in single frog cardiac cells by quinidine flecainide ethmozin and ethacizin. Am. J. Physiol. 1989 256(3 Pt 1) C549-C559.
95. Zhang Y.H.; Hancox J.C. Mode-dependent inhibition by quinidine of Na+-Ca2+ exchanger current from guinea-pig isolated ventricular myocytes. Clin. Exp. Pharmacol. Physiol. 2002 29(9) 777-781.
96. Mitcheson J.S.; Hancox J.C. Modulation by mexiletine of action potentials L-type Ca current and delayed rectifier K current recorded from isolated rabbit atrioventricular nodal myocytes. Pflugers Arch. 1997 434(6) 855-858. (Pubitemid 28066438)
97. Rivet M.; Bois P.; Cognard C.; Raymond G. Phenytoin preferentially inhibits L-type calcium currents in whole-cell patch-clamped cardiac and skeletal muscle cells. Cell Calcium 1990 11(9) 581-588.
98. Yatani A.; Hamilton S.L.; Brown A.M. Diphenylhydantoin blocks cardiac calcium channels and binds to the dihydropyridine receptor. Circ. Res. 1986 59(3) 356-361. (Pubitemid 17178130)
99. Xu Y.Q.; Pickoff A.S.; Clarkson C.W. Evidence for developmental changes in sodium channel inactivation gating and sodium channel block by phenytoin in rat cardiac myocytes. Circ. Res. 1991 69(3) 644-656.
100. Ramos E.; O'Leary M.E. State-dependent trapping of flecainide in the cardiac sodium channel. J. Physiol. 2004 560(Pt 1) 37-49. (Pubitemid 39406015)
101. Yang B.F.; Du Z.M.; Kohei S. Frequency-And voltage-dependent inhibition of delayed outward potassium current by flecainide in isolated atrial cell of guinea pig heart. Zhongguo Yao Li Xue Bao 1994 15(1) 28-32. (Pubitemid 24033065)
102. Delgado C.; Tamargo J.; Henzel D.; Lorente P. Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Br. J. Pharmacol. 1993 108(3) 721-727. (Pubitemid 23067943)
103. Hancox J.C.; Mitcheson J.S. Inhibition of L-type calcium current by propafenone in single myocytes isolated from the rabbit atrioventricular node. Br. J. Pharmacol. 1997 121(1) 7-14. (Pubitemid 27192782)
104. Undrovinas A.I.; Belardinelli L.; Undrovinas N.A.; Sabbah H.N. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc. Electrophysiol. 2006 17 Suppl 1 S169-S177.
105. Szél T.; Koncz I.; Jost N.; Baczkó I.; Husti Z.; Virág L.; Bussek A.; Wettwer E.; Ravens U.; Papp J.G.; Varró A. Class I/B antiarrhythmic property of ranolazine a novel antianginal agent in dog and human cardiac preparations. Eur. J. Pharmacol. 2011 662(1-3) 31-39.
106. Allen T.J.; Chapman R.A. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br. J. Pharmacol. 1996 118(2) 249-254. (Pubitemid 26149270)
107. Zahradníková A.; Minarovic I.; Zahradník I. Competitive and cooperative effects of Bay K 8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J. Pharmacol. Exp. Ther. 2007 322(2) 638-645. (Pubitemid 47105781)
108. Noguchi K.; Masumiya H.; Takahashi K.; Kaneko K.; Higuchi S.; Tanaka H.; Shigenobu K. Comparative effects of gallopamil and verapamil on the mechanical and electrophysiological parameters of isolated guinea-pig myocardium. Can. J. Physiol. Pharmacol. 1997 75(12) 1316-1321. (Pubitemid 28130371)
109. De Paoli P.; Cerbai E.; Koidl B.; Kirchengast M.; Sartiani L.; Mugelli A. Selectivity of different calcium antagonists on T-And L-type calcium currents in guinea-pig ventricular myocytes. Pharmacol. Res. 2002 46(6) 491-497. (Pubitemid 35435690)
110. Meier C.F.; Briggs G.M.; Claycomb W.C. Electrophysiological properties of cultured adult rat ventricular cardiac muscle cells. Am. J. Physiol. 1986 250(5 Pt 2) H731-735.
111. Woods J.P.; West T.C. Frequency-dependence of Vmax in Kdepolarized guinea pig ventricle: effects of nifedipine and verapamil. J. Cardiovasc. Pharmacol. 1985 7(1) 197-204. (Pubitemid 15162264)
112. Osterrieder W. Inhibition of the fast Na+ inward current by the Ca2+ channel blocker tiapamil. J. Cardiovasc. Pharmacol. 1986 8(6) 1101-1106. (Pubitemid 17211571)
113. Rosen M.R.; Ilvento J.P.; Gelband H.; Merker C. Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. J. Pharmacol. Exp. Ther. 1974 189(2) 414-422.
114. Danilo P.; Reder R.F.; Binah O.; Legato M.J. Fetal canine cardiac Purkinje fibers: electrophysiology and ultrastructure. Am. J. Physiol. 1984 246(2 Pt 2) H250-260. (Pubitemid 14143713)
115. Prakash P.; Tripathi O. Verapamil and TTX inhibit V+ max but differentially alter the duration of action potential of adult chicken ventricular myocardium. Indian J. Biochem. Biophys. 1998 35(2) 123-130. (Pubitemid 128374875)
116. Horackova M. The effect of D600 on tonic tension Na+ inward current and Na+-Ca2+ exchange in frog heart. Can. J. Physiol. Pharmacol. 1985 63(11) 1404-1410. (Pubitemid 16204574)
117. Hume J.R. Comparative interactions of organic Ca++ channel antagonists with myocardial Ca++ and K+ channels. J. Pharmacol. Exp. Ther. 1985 234(1) 134-140. (Pubitemid 15034901)
118. Nawrath H.; Eick R.E.; McDonald T.F.; Trautwein W. On the mechanism underlying the action of D-600 on slow inward current and tension in mammalian myocardium. Circ. Res. 1977 40(4) 408-414. (Pubitemid 8074244)
119. McDonald T.F.; Pelzer D.; Trautwein W. Cat ventricular muscle treated with D600: characteristics of calcium channel block and unblock. J. Physiol. 1984 352 217-241. (Pubitemid 14059617)
120. Galper J.B.; Catterall W.A. Inhibition of sodium channels by D600. Mol. Pharmacol. 1979 15(1) 174-178. (Pubitemid 9150369)
121. Bean B.P. Nitrendipine block of cardiac calcium channels: highaffinity binding to the inactivated state. Proc. Natl. Acad. Sci. U. S. A. 1984 81(20) 6388-6392. (Pubitemid 15220843)
122. Lee K.S.; Tsien R.W. Mechanism of calcium channel blockade by verapamil D600 diltiazem and nitrendipine in single dialysed heart cells. Nature 1983 302(5911) 790-794. (Pubitemid 13125114)
123. Yatani A.; Brown A.M. The calcium channel blocker nitrendipine blocks sodium channels in neonatal rat cardiac myocytes. Circ. Res. 1985 56(6):868-875. (Pubitemid 15231510)
124. Charnet P.; Ouadid H.; Richard S.; Nargeot J. Electrophysiological analysis of the action of nifedipine and nicardipine on myocardial fibers. Fundam. Clin. Pharmacol. 1987 1(6) 413-431. (Pubitemid 18060731)
125. Gotoh Y.; Imaizumi Y.; Watanabe M.; Shibata E.F.; Clark R.B.; Giles W.R. Inhibition of transient outward K+ current by DHP Ca2+ antagonists and agonists in rabbit cardiac myocytes. Am. J. Physiol. 1991 260(5 Pt 2) H1737-1742.
126. Sun H.; Chartier D.; Nattel S.; Leblanc N. Ca2+-Activated Cl-current can be triggered by Na+ current-induced SR Ca2+ release in rabbit ventricle. Am. J. Physiol. 1999 277(4 Pt 2) H1467-H1477. (Pubitemid 29522678)
127. Sanguinetti M.C.; Kass R.S. Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists. Circ. Res. 1984 55(3) 336-348. (Pubitemid 14047495)
128. Richard S.; Charnet P.; Ouadid H.; Tiaho F.; Nargeot J. Effects of the Ca-Antagonist nicardipine on K+ currents and Na+-Ca2+ exchange in frog atrial fibres. J. Mol. Cell. Cardiol. 1988 20(12) 1133-1140. (Pubitemid 19059023)
129. Iijima T.; Yanagisawa T.; Taira N. Increase in the slow inward current by intracellularly applied nifedipine and nicardipine in single ventricular cells of the guinea-pig heart. J. Mol. Cell. Cardiol. 1984 16(12) 1173-1177. (Pubitemid 15013891)
130. Mitsuiye T.; Guo J.; Noma A. Nicardipine-sensitive Na+-mediated single channel currents in guinea-pig sinoatrial node pacemaker cells. J. Physiol. 1999 521 Pt 1 69-79.
131. Koidl B.; Miyawaki N.; Tritthart H.A. A novel benzothiazine Ca2+ channel antagonist semotiadil inhibits cardiac L-type Ca2+ currents. Eur. J. Pharmacol. 1997 322(2-3) 243-247. (Pubitemid 27122900)
132. Yamamoto M.; Gotoh Y.; Imaizumi Y.; Watanabe M. Mechanisms of long-lasting effects of benidipine on Ca current in guineapig ventricular cells. Br. J. Pharmacol. 1990 100(4) 669-676. (Pubitemid 20233301)
133. Masumiya H Shijuku T Tanaka H Shigenobu K. Inhibition of myocardial L-And T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur. J. Pharmacol. 1998 349(2-3) 351-357. (Pubitemid 28277107)
134. Kohlhardt M.; Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 1977 298(3) 267-272. (Pubitemid 8140649)
135. Missan S.; Zhabyeyev P.; Dyachok O.; Jones S.E.; McDonald T.F. Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br. J. Pharmacol. 2003 140(5) 863-870. (Pubitemid 37464068)
136. Himmel H.M.; Glossmann H.; Ravens U. Naftopidil a new alpha-Adrenoceptor blocking agent with calcium antagonistic properties: characterization of Ca2+ antagonistic effects. J. Cardiovasc. Pharmacol. 1991 17(2) 213-221.
137. Bénitah J.P.; Bailly P.; D'Agrosa M.C.; Da Ponte J.P.; Delgado C.; Lorente P. Slow inward current in single cells isolated from adult human ventricles. Pflugers Arch. 1992 421(2-3) 176-187.
138. Amerini S.; Giotti A.; Mugelli A. Effect of verapamil and diltiazem on calcium-dependent electrical activity in cardiac Purkinje fibres. Br. J. Pharmacol. 1985 85(1) 89-96. (Pubitemid 15093549)
139. Nagao T.; Narita H.; Sato M.; Nakajima H.; Kiyomoto A. Development of diltiazem a calcium antagonist: coronary vasodilating and antihypertensive actions. Clin. Exp. Hypertens. A. 1982 4(1-2) 285-296. (Pubitemid 12110525)
140. Hashimoto Y.; Yabana H.; Murata S. Electrophysiological effect of l-cis-diltiazem the stereoisomer of d-cis-diltiazem on isolated guinea-pig left ventricular myocytes. Eur. J. Pharmacol. 2000 391(3) 217-223. (Pubitemid 30154087)
141. Sunami A.; Fan Z.; Nitta J.; Hiraoka M. Two components of usedependent block of Na+ current by disopyramide and lidocaine in guinea pig ventricular myocytes. Circ. Res. 1991 68(3) 653-661.
142. Lopaschuk G.D.; Barr R.; Wambolt R. Effects of diltiazem on glycolysis and oxidative metabolism in the ischemic and ischemic/reperfused heart. J. Pharmacol. Exp. Ther. 1992 260(3) 1220-1228.
143. Itogawa E.; Kurosawa H.; Yabana H.; Murata S. Protective effect of l-cis-diltiazem on hypercontracture of rat myocytes induced by veratridine. Eur. J. Pharmacol. 1996 317(2-3) 401-406. (Pubitemid 27014048)
144. Emanuel K.; Mackiewicz U.; Pytkowski B.; Lewartowski B. Effects of mibefradil a blocker of T-type Ca2+ channels in single myocytes and intact muscle of guinea-pig heart. J. Physiol. Pharmacol. 1998 49(4) 577-590. (Pubitemid 29024375)
145. Masumiya H.; Kase J.; Tanaka Y.; Tanaka H.; Shigenobu K. Effects of mibefradil a selective T-type Ca2+ channel antagonist on sino-Atrial node and ventricular myocardia. Res. Commun. Mol. Pathol. Pharmacol. 1999 104(3) 321-329. (Pubitemid 30158753)
146. Pinto J.M.; Sosunov E.A.; Gainullin R.Z.; Rosen M.R.; Boyden P.A. Effects of mibefradil a T-type calcium current antagonist on electrophysiology of Purkinje fibers that survived in the infarcted canine heart. J. Cardiovasc. Electrophysiol. 1999 10(9) 1224-1235. (Pubitemid 29451683)
147. Protas L.; Robinson R.B. Mibefradil an I(Ca,T) blocker effectively blocks I(Ca,L) in rabbit sinus node cells. Eur. J. Pharmacol. 2000 401(1) 27-30. (Pubitemid 30479808)
148. Chuang R.S.; Jaffe H.; Cribbs L. Perez-Reyes E.; Swartz K.J. Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat. Neurosci. 1998 1(8) 668-674. (Pubitemid 128406377)
149. Sidach S.S.; Mintz I.M. Kurtoxin a gating modifier of neuronal high-And low-threshold ca channels. J. Neurosci. 2002 22(6) 2023-2034. (Pubitemid 35386503)
150. Rosati B.; Dun W.; Hirose M.; Boyden P.A.; McKinnon D. Molecular basis of the T-And L-type Ca2+ currents in canine Purkinje fibres. J. Physiol. 2007 579(Pt 2) 465-471. (Pubitemid 46351762)
151. Horiba M.; Muto T.; Ueda N.; Opthof T.; Miwa K.; Hojo M.; Lee J.K.; Kamiya K.; Kodama I.; Yasui K. T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers. Life Sci. 2008 82(11-12) 554-560.
152. Catterall W.A.; Perez-Reyes E.; Snutch T.P.; Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 2005 57(4) 411-425. (Pubitemid 43036432)
153. Tikhonov D.B.; Zhorov B.S. Possible roles of exceptionally conserved residues around the selectivity filters of sodium and calcium channels. J. Biol. Chem. 2011 286(4) 2998-3006.
154. Heinemann S.H.; Schlief T.; Mori Y.; Imoto K. Molecular pore structure of voltage-gated sodium and calcium channels. Braz. J. Med. Biol. Res. 1994 27(12) 2781-2802.
155. Heinemann S.H.; Terlau H.; Stühmer W.; Imoto K.; Numa S. Calcium channel characteristics conferred on the sodium channel by single mutations. Nature 1992 356(6368) 441-443.
156. Lopreato G.F.; Lu Y.; Southwell A; Atkinson N.S.; Hillis D.M.; Wilcox T.P.; Zakon H.H. Evolution and divergence of sodium channel genes in vertebrates. Proc. Natl. Acad. Sci. U. S. A. 2001 98(13) 7588-7592. (Pubitemid 32567992)
157. Vornanen M.; Hassinen M.; Haverinen J. Tetrodotoxin sensitivity of the vertebrate cardiac Na+ current. Mar. Drugs 2011 9(11) 2409-2422.
158. Geffeney S.L.; Fujimoto E.; Brodie E.D. 3rd; Brodie E.D.; Ruben P.C. Evolutionary diversification of TTX-resistant sodium channels in a predator-prey interaction. Nature 2005 434(7034) 759-763. (Pubitemid 44739518)
159. Tang Z.Z.; Liang M.C.; Lu S.; Yu D.; Yu C.Y.; Yue D.T.; Soong T.W. Transcript scanning reveals novel and extensive splice variations in human l-type voltage-gated calcium channel Cav1.2 alpha1 subunit. J. Biol. Chem. 2004 279(43) 44335-44343. (Pubitemid 39430838)
160. Fozzard H.A.; Lipkind G.M. The tetrodotoxin binding site is within the outer vestibule of the sodium channel. Mar. Drugs 2010 8(2) 219-234.
161. Lipkind G.M.; Fozzard H.A. A structural model of the tetrodotoxin and saxitoxin binding site of the Na+ channel. Biophys. J. 1994 66(1) 1-13. (Pubitemid 24016478)
162. Tikhonov D.B.; Zhorov B.S. Modeling P-loops domain of sodium channel: homology with potassium channels and interaction with ligands. Biophys. J. 2005 88(1) 184-197. (Pubitemid 40070668)
163. Jiang Y.; Lee A.; Chen J.; Cadene M.; Chait B.T.; MacKinnon R. The open pore conformation of potassium channels. Nature 2002 417(6888) 523-526. (Pubitemid 34595913)
164. Payandeh J.; Scheuer T.; Zheng N.; Catterall W.A. The crystal structure of a voltage-gated sodium channel. Nature 2011 475 353-358.
165. Payandeh J.; Gamal El-Din T.M.; Scheuer T.; Zheng N.; Catterall W.A. Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. Nature 2012 486 135-139.
166. Zhang X.; Ren W.; DeCaen P.; Yan C.; Tao X.; Tang L.; Wang J.; Hasegawa K.; Kumasaka T.; He J.; Clapham D.E.; Yan N. Crystal structure of an orthologue of the NaChBac voltagegated sodium channel. Nature 2012 486 130-134.
167. Welling A.; Ludwig A.; Zimmer S.; Klugbauer N.; Flockerzi V.; Hofmann F. Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ. Res. 1997 81(4) 526-532. (Pubitemid 27432739)
168. Hockerman G.H.; Peterson B.Z.; Johnson B.D.; Catterall W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. 1997 37 361-396. (Pubitemid 27238881)
169. Sheets M.F.; Fozzard H.A.; Lipkind G.M.; Hanck D.A. Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc. Med. 2010 20(1) 16-21.
170. Xiao Y.F.; Ke Q.; Wang S.Y.; Yang Y.; Wang G.K.; Morgan J.P.; Leaf A. Point mutations in alpha-subunit of human cardiac Na+ channels alter Na+ current kinetics. Biochem. Biophys. Res. Commun. 2001 281(1) 45-52. (Pubitemid 32924397)
171. Hofmann F.; Lacinová L.; Klugbauer N. Voltage-dependent calcium channels: from structure to function. Rev. Physiol. Biochem. Pharmacol. 1999 139 33-87.
172. Doyle D.A.; Morais Cabral J.; Pfuetzner R.A.; Kuo A.; Gulbis J.M.; Cohen S.L.; Chait B.T.; MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998 280(5360) 69-77. (Pubitemid 28169082)
173. Zhorov B.S.; Tikhonov D.B. Potassium sodium calcium and glutamate-gated channels: pore architecture and ligand action. J. Neurochem. 2004 88(4) 782-799. (Pubitemid 38199299)
174. Gutman G.A.; Chandy K.G.; Grissmer S.; Lazdunski M. McKinnon D.; Pardo L.A.; Robertson G.A.; Rudy B.; Sanguinetti M.C.; Stühmer W.; Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 2005 57(4) 473-508. (Pubitemid 43036437)
175. Liu Z.; Du L.; Li M. Update on the slow delayed rectifier potassium current (I(Ks)): role in modulating cardiac function. Curr. Med. Chem. 2012 19(9) 1405-1420.
176. Scholz A. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br. J. Anaesth. 2002 89(1) 52-61. (Pubitemid 34778103)
177. Valenzuela C.; Delpón E.; Tamkun M.M.; Tamargo J.; Snyders D.J. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys. J. 1995 69(2) 418-427.
178. Iost N.; Virág L.; Varró A.; Papp J.G. Comparison of the effect of class IA antiarrhythmic drugs on transmembrane potassium currents in rabbit ventricular myocytes. J. Cardiovasc. Pharmacol. Ther. 2003 8(1) 31-41. (Pubitemid 36363209)
179. Zhang S.; Sawanobori T.; Hirano Y.; Hiraoka. M. Multiple modulations of action potential duration by different calcium channel blocking agents in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 1997 30(4) 489-496. (Pubitemid 27527585)
180. Rauer H.; Grissmer S. The effect of deep pore mutations on the action of phenylalkylamines on the Kv1.3 potassium channel. Br. J. Pharmacol. 1999 127(5) 1065-1074. (Pubitemid 29326627)
181. Zhabyeyev P.; Missan S.; Jones S.E.; McDonald T.F. Lowaffinity block of cardiac K(+) currents by nifedipine. Eur. J. Pharmacol. 2000 401(2) 137-143. (Pubitemid 30488188)
182. Jahnel U.; Klemm P.; Nawrath H. Different mechanisms of the inhibition of the transient outward current in rat ventricular myocytes. Naunyn Schmiedebergs Arch. Pharmacol. 1994 349(1) 87-94. (Pubitemid 24045026)
183. Zhang X.; Anderson J.W.; Fedida D. Characterization of nifedipine block of the human heart delayed rectifier hKv1.5. J. Pharmacol. Exp. Ther. 1997 281(3) 1247-1256. (Pubitemid 27258384)
184. Chouabe C.; Drici M.D.; Romey G.; Barhanin J.; Lazdunski M. HERG and KvLQT1/IsK the cardiac K+ channels involved in long QT syndromes are targets for calcium channel blockers. Mol. Pharmacol. 1998 54(4) 695-703. (Pubitemid 28480973)
185. Wang J.; Salata J.J.; Bennett P.B. Saxitoxin is a gating modifier of HERG K+ channels. J. Gen. Physiol. 2003 121(6) 583-598. (Pubitemid 36682922)
186. Jost N.; Kohajda Z.; Kristóf A.; Kovács P.P.; Husti Z.; Juhász V.; Kiss L.; Varró A.; Virág L.; Baczkó I. Atrial remodeling and novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation. Curr. Med. Chem. 2011 18(24) 3675-3694.
187. Yagami T; Kohma H.; Yamamoto Y. L-type voltage-dependent calcium channels as therapeutic targets for neurodegenerative diseases. Curr. Med. Chem. 2012 19(28) 4816-4827.
188. Moretti A.; Gorini A.; Villa R.F. Pharmacotherapy and prevention of vascular dementia. CNS Neurol. Disord. Drug Targets. 2011 10(3) 370-390.
189. Jaggi A.S.; Singh N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol. Disord. Drug Targets. 2011 10(5) 589-609.